Stephen Smolinski - 04 Jan 2022 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Commercial Officer
Signature
/s/ Christopher Sullivan, Attorney-in-Fact
Issuer symbol
AVTX
Transactions as of
04 Jan 2022
Net transactions value
$0
Form type
4
Filing time
06 Jan 2022, 15:19:56 UTC
Previous filing
06 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $0 +400,000 $0.000000 400,000 04 Jan 2022 Common Stock 400,000 $1.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date.